StingNCT01089465
Cimex Lectularius or Bed Bugs : Vector of Infectious Agents and Pathogenic Role
A study testing Collection of the bedbugs and dermatological follow-up of the stings in people with Sting, run by Centre Hospitalier Universitaire de Nice at 1 site in France.
Trial summary
During the last years, the investigators were the witness to the increase of a old emerging pest due to bed bugs (Cimex lectularius) in the world. Insecticides resistances apparitions and internationals transports increases seem to be the reasons of the pest. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Sting
- What is being tested?
- Collection of the bedbugs and dermatological follow-up of the stings
- How many people
- 135 participants
- Where
- 1 siteFrance
- Study dates
- Mar 2010to 31 Dec 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- On the site of takings presence of insects and eggs evoking bedbugs of beds. The identification of certainty will be made in the laboratory. All the insects not apartment to the family of Cimicidae (Criterion of exclusion) are thrown(cast) in trash cans of laboratories for organic products.
- voluntary Patients after reading of the information sheet and the signature of the consent
- Membership of the patient in the national insurance scheme
Who cannot join
- On the site of takings absence of insects and eggs evoking bedbugs of beds
- During the identification of certainty in the laboratory, the captured insects do not make parties of the family of Cimicidae
- The subjects deprived of freedom.
- Patients cancelling their consent.
- Patients violating the protocol of search(research)
Trial locations and contacts
1 site in 1 country.
France1 site
Collection of the bedbugs and dermatological follow-up of the stings
Nice, 06000
About this study
During the last years, the investigators were the witness to the increase of a old emerging pest due to bed bugs (Cimex lectularius) in the world. Insecticides resistances apparitions and internationals transports increases seem to be the reasons of the pest. Cimex lectularius as vector of parasites, bacteria or virus was often suggested although not much observation are recently investigated in France. This study intends to examine the vectorial ability and the direct pathogenicity of Cimex lectularius.
- Conditions
- Sting
- Being tested
- Collection of the bedbugs and dermatological follow-up of the stings
- Keywords
- Bed bugs, Cimex, insects, bites
- Medical subject headings
- Bites and Stings
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Collection of the bedbugs and dermatological follow-up of the stingsOther
Collection of the bedbugs and dermatological follow-up of the stings at J1 J7 J14 J21 J28
What is being measured
The primary outcome is the main question the study is designed to answer.
Morphological identification of every bedbug Porterage of bacterial agents Porterage of viral agents Biomolecular identification of the insect A breeding of bedbugs Tests of sensibility in insecticides
Measured: day 1
Secondary outcomes (1)
Study of the direct pathogenicity of lectularius C.
During each of four consultations a questionnaire and a descriptive index card(form) of the general and dermatological signs will be informed. The criteria of evaluation, associated with anonimisées photos, are split into two groups: general Signs and dermatological Signs
Measured: day 1, 7, 15 and 30
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Mar 2010 (estimated)
- Study startMar 2010
- Primary completionMar 2012
- Study completion31 Dec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for StingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 135 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de Nice
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Pascal Delaunay, Dr, Principal investigator, Centre Hospitalier Universitaire de Nice
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01089465
- Sponsor's protocol ID
- 09-API-01
- Status last verified
- Apr 2024
- First submitted
- 12 Mar 2010
- Last updated
- 12 Apr 2024
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cimex Lectularius or Bed Bugs : Vector of Infectious Agents and Pathogenic Role
- ClinicalTrials.gov ID
- NCT01089465
- Acronym / sponsor ID
- 09-API-01
- Conditions
- Sting
- Keywords
- Bed bugs, Cimex, insects, bites
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 135 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire de NiceUniversity, hospital or other
- Study start
- Mar 2010 (actual)
- Primary completion
- Mar 2012 (actual)
- Study completion
- 31 Dec 2019 (actual)
- First posted
- 18 Mar 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
During the last years, the investigators were the witness to the increase of a old emerging pest due to bed bugs (Cimex lectularius) in the world. Insecticides resistances apparitions and internationals transports increases seem to be the reasons of the pest. Cimex lectularius as vector of parasites, bacteria or virus was often suggested although not much observation are recently investigated in France. This study intends to examine the vectorial ability and the direct pathogenicity of Cimex lectularius.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- On the site of takings presence of insects and eggs evoking bedbugs of beds. The identification of certainty will be made in the laboratory. All the insects not apartment to the family of Cimicidae (Criterion of exclusion) are thrown(cast) in trash cans of laboratories for organic products.
- voluntary Patients after reading of the information sheet and the signature of the consent
- Membership of the patient in the national insurance scheme
Key exclusion criteria (5 listed)
- On the site of takings absence of insects and eggs evoking bedbugs of beds
- During the identification of certainty in the laboratory, the captured insects do not make parties of the family of Cimicidae
- The subjects deprived of freedom.
- Patients cancelling their consent.
- Patients violating the protocol of search(research)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Collection of the bedbugs and dermatological follow-up of the stingsCollection of the bedbugs and dermatological follow-up of the stings at J1 J7 J14 J21 J28 | Other | – |
Primary outcome
Morphological identification of every bedbug Porterage of bacterial agents Porterage of viral agents Biomolecular identification of the insect A breeding of bedbugs Tests of sensibility in insecticides
Time frame: day 1
1 secondary outcome
Study of the direct pathogenicity of lectularius C.
Time frame: day 1, 7, 15 and 30
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Apr 2024.
Related trials for Sting
RecruitingPhase 1
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Multiple Myeloma (MM)
Recruiting
Evaluating the Impacts of Informal Tick and Tickborne Disease Educational Tools on Children
Tick Bites
Recruiting
The Tick App: Changing Behaviors With Educational Messaging
Tick Bites
RecruitingPhase 2
Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
Metastatic Renal Cell Carcinoma ( mRCC), OligoProgressive Metastatic Disease
RecruitingPhase 2
MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
Multiple Myeloma, Newly Diagnosed
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pascal Delaunay, Dr principal investigator
Centre Hospitalier Universitaire de Nice
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Collection of the bedbugs and dermatological follow-up of the stings in people with Sting, run by Centre Hospitalier Universitaire de Nice at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Morphological identification of every bedbug Porterage of bacterial agents Porterage of viral agents Biomolecular identification of the insect A breeding of bedbugs Tests of sensibility in insecticides (time frame: day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Apr 2024.